3篇
您的检索式：作者名="Jesse Civan"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma after Iocoregional therapy:Magnetic resonance imaging findings in falsely negative exams显示文摘AIM:To elucidate causes for false negative magnetic resonance imaging(MRI)exams by identifying imaging characteristics that predict viable hepatocellular carcinoma(HCC)in lesions previously treated with locoregional therapy when obvious findings of recurrence are absent.METHODS:This retrospective institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study included patients who underwent liver transplantation at our center between 1/1/2000 and 12/31/2012 after being treated for HCC with locoregional therapy.All selected patients had a contrast-enhanced MRI after locoregional therapy within 90 d of transplant that was prospectively interpreted as without evidence of residual or recurrenttumor.Retrospectively,2 radiologists,blinded to clinica and pathological data,independently reviewed the pre transplant MRIs for 7 imaging features.Liver explan histopathology provided the reference standard,with clinically significant tumor defined as viable tumor≥1.0cm in maximum dimension.Fisher’s exact test was firs performed to identify significant imaging features.RESULTS:Inclusion criteria selected for 42 patients with 65 treated lesions.Fourteen of 42 patients(33%and 16 of 65 treated lesions(25%)had clinically significant viable tumor on explant histology.None o the 7 imaging findings examined could reliably and reproducibly determine which treated lesion had viable tumor when the exam had been prospectively read as without evidence of viable HCC.CONCLUSION:After locoregional therapy some treated lesions that do not demonstrate any MRI evidence o HCC will contain viable tumor.As such even patients with a negative MRI following treatment should receive regular short-term imaging surveillance because some have occult viable tumor.The possibility of occult tumo should be a consideration when contemplating any action which might delay liver transplant. | David Becker-Weidman Jesse M Civan Sandeep P Deshmukh Christopher G Roth Steven K Herrine Laurence Parker Donald G Mitchell | 2016 | World Journal of Hepatology2016，8，16： | 2 |
| 2 | Genetic variations in colorectal cancer risk and clinical outcome显示文摘Colorectal cancer(CRC)has an apparent hereditary component,as evidenced by the well-characterized genetic syndromes and family history associated with the increased risk of this disease.However,in a large fraction of CRC cases,no known genetic syndrome or family history can be identified,suggesting the presence of'missing heritability'in CRC etiology.The genome-wide association study(GWAS)platform has led to the identification of multiple replicable common genetic variants associated with CRC risk.These newly discovered genetic variations might account for a portion of the missing heritability.Here,we summarize the recent GWASs related to newly identified genetic variants associated with CRC risk and clinical outcome.The findings from these studies suggest that there is a lack of understanding of the mechanism of many single nucleotide polymorphisms(SNPs)that are associated with CRC.In addition,the utility of SNPs as prognostic markers of CRC in clinical settings remains to be further assessed.Finally,the currently validated SNPs explain only a small fraction of total heritability in complex-trait diseases like CRC.Thus,the'missing heritability'still needs to be explored further.Future epidemiological and functional investigations of these variants will add to our understanding of CRC pathogenesis,and may ultimately lead to individualized strategies for prevention and treatment of CRC. | Kejin Zhang Jesse Civan Sushmita Mukherjee Fenil Patel Hushan Yang | 2014 | World Journal of Gastroenterology2014，20，15： | 1 |
| 3 | Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?显示文摘 | Jesse Civan Hie Won Hann | 2015 | Expert Opinion on Drug Safety2015，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员